Shots:

• The approval is based on trial results assessing reSET-O in 170 patients receiving either treatment-as-usual (TAU) + standard clinician interactions + buprenorphine or reSET-O + standard clinician interactions + buprenorphine for 12 wks.
• The study demonstrated improved and increase rates of retention time with efficacy results in patients with OUD
• reSET-O is a FDA approved Prescription Digital Therapeutic mobile medical application for 12 weeks- delivering a cognitive behavioral therapy for OUD patients aged ≥18 yrs. In Nov 2018- reSET received FDA approval for Substance Use Disorder (SUD)

Ref: Novartis | Image: Medical Product Outsourcing